Boardroom Alpha
Start trial
8-K primary document
OSRH · Current Report (Form 8-K) · Filed August 7, 2026

Osr Health Inc — 8-K exhibit

ea030111401ex99-1.htm
Osr Health Inc on Boardroom Alpha

Exhibit 99.1

 

OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program

 

BELLEVUE, WA / ACCESS Newswire / August 7, 2026 / OSR Health, Inc. (NASDAQ: OSRH) (“OSR Health” or the “Company”) today issued a clarification regarding its press release dated July 31, 2026 concerning the Nasdaq Stock Market (“Nasdaq”) and the Company’s Shareholder Loyalty CVR Program.

 

The Company is clarifying that the statement in the prior release, “The communication affirms that our loyalty program is additive and gives shareholders clarity,” should not be interpreted as indicating that Nasdaq has approved or endorsed the Shareholder Loyalty CVR Program.

 

Nasdaq’s earlier communication was a preliminary, verbal indication limited to the technical question of whether the program would result in a mechanical adjustment to the price of OSRH common stock (such as an ex-date adjustment). Other than that, Nasdaq has not expressed any definitive opinion regarding the program.

 

This clarification does not change the Company’s previously announced August 14, 2026 record date for the Shareholder Loyalty CVR Program. Program details, eligibility, and enrollment information remain available at www.osr-health.com/loyaltyprogram.

 

The Company will update shareholders as matters progress.

 

About OSR Health

 

OSR Health, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Health engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.osr-health.com

 

Investor Contact

 

OSR Health, Inc.
Investor Relations
ir@osr-health.com

 

Forward-Looking Statements

 

This press release contains forward-looking statements, including statements regarding the Shareholder Loyalty CVR Program and the Company’s regulatory and securities-law processes. These statements are subject to risks and uncertainties, including the outcome and timing of the Company’s pending SEC no-action request, Nasdaq’s ultimate position on the program, the satisfaction of the program’s holding-period and price conditions, the Company’s continued listing on Nasdaq, and other factors described in the Company’s SEC filings. Actual results may differ materially. The Company undertakes no obligation to update any forward-looking statement except as required by law. This release does not constitute an offer to sell or a solicitation to buy any securities.

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer